Effect of dialysis duration on serum calcium and phosphorous in hemodialysis patients

Abstract
In many countries, physicians follow clinical guidelines for mineral bone disorders to control secondary hyperparathyroidism associated with serum calcium and phosphorous level in patients maintaining hemodialysis (HD). The current research was conducted among 34 patients with chronic renal insufficiency on maintenance HD to study serum Phosphorous, Calcium, Alkaline phosphatase changes in maintenance hemodialysed patients.

Keywords: renal insufficiency, renal dialysis, calcium, phosphorous, biomarkers

Introduction
Chronic renal insufficiency is associated with changes in mineral and bone metabolism biochemistry and density. In many countries, physicians follow clinical guidelines for mineral bone disorders to control secondary hyperparathyroidism associated with serum calcium and phosphorous level in patients maintaining hemodialysis (HD). With the begin of hemodialysis, histological marks of secondary hyperparathyroidism could be seen in bones of over 50 percent of end stage renal disease (ESRD) patients, skeletal defects identified as Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) (the so called as renal osteodystrophy) consist of some types of bone tissue lesions, such as the most widespread high bone turn-over disease but also the a dynamic bone disease.

Other less common bone diseases such as osteomalacia, aluminum-related bone disease, fluorosis and strontium overload or mixed types also have been pronounced.

It is well recognized that bone mineral density (BMD) is decreased in patients suffering chronic renal failure and they have higher fracture risk. Uremic patients frequently reveal high serum concentration of biochemical markers.

The aim of current research is to study serum Phosphorous (P), Calcium (Ca), alkaline phosphatase (ALP) changes and other indices in hemodialysed patients.

Methods
Participants
Thirty four patients, 16 postmenopausal female and 18 male, on maintenance HD were involved in the current study after obtaining their informed consent. The study was conducted in Golestan University of Medical Sciences, Gorgan, Iran during the period February-May 2018. Patients mean age was 57.8 with range of 43-73 years old, with the mean HD duration of 40 months (range: 11-204 months). All of our patients were treated by conventional HD 3-4 hours, three times in a week. None of the patients had a past history of renal transplantation or parathyroidectomy, history of radiographic evidence of rib, vertebral or hip fracture. At the time of the assessment, none of the patients, especially the postmenopausal women, were receiving or had received previously oestrogen or raloxifene, bisphosphonates, calcitonin, PTH or corticosteroids agents. None of the participants had received previously oestrogen or raloxifene, bisphosphonates, calcitonin, PTH or corticosteroids agents. None of the participants had received previously oestrogen or raloxifene, bisphosphonates, calcitonin, PTH or corticosteroids agents. None of the participants had received previously oestrogen or raloxifene, bisphosphonates, calcitonin, PTH or corticosteroids agents. None of the participants had received previously oestrogen or raloxifene, bisphosphonates, calcitonin, PTH or corticosteroids agents.

Biochemistry
Morning pre-midweek hemodialysis blood samplings were

Abbreviations: P, Phosphorous; Ca, Calcium; ALP, alkaline phosphatase; BMD, bone mineral density; CKD-MBD, chronic kidney disease-mineral and bone disorder; HD, hemodialysis; ESRD, end stage renal disease

Volume 2 Issue 3 - 2018

Seyyed Mohsen Hosseininejad, Mehrdad Aghaei, Gholamreza Rosnehand, Fateme Sadat Hosseininejad, Asiyeh Moazzami, Robabeh Salehi, Saied Amirkhanlou
1Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
2Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3Golestan University of Medical Sciences, Gorgan, Iran
4Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
5School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran
6Hemodialysis Ward, 5th Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
7Clinical Research Development Unit (CRDU), Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
8Hemodialysis Ward, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran

Correspondence: Saied Amirkhanlou, Clinical Research Development Unit (CRDU), Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran, Tel 009899398387874 Email Drsam74ir@gmail.com

Received: June 06, 2018 | Published: June 18, 2018

©2018 Hosseininejad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.
collected from the arteriovenous fistula after a 12hr fasting. The serum obtained after centrifugation was kept in aliquots at −20°C until analyzed, with measurements made instantly after defrosting.

Serum calcium, phosphorus, creatinine, and total alkaline phosphatase etc. were assessed routinely using an automatic analyzer.

Statistics

All obtained results are presented as mean ±SD, unless otherwise indicated. Correlations between variables were calculated using simple linear regression and p<0.05 was considered as statistically significant. Comparison of variables was done using chi-square and/or student t-test analysis.

Results

Demographic and biochemical data of thirty four patients, consisting of 18 male and 16 postmenopausal female, on maintenance HD were investigated.

Table 1 depicts the demographic data for the 34 patients and table 2 for the 18 male patients. Table 2 represents the biochemical data for all 34 patients.

The results of our study also showed that with dialysis increase, the serum biomarkers of Ca, P and Alkaline phosphatase decrease; the correlations were statistically significant.

Table 1 Age and time-on-dialysis of the participants

<table>
<thead>
<tr>
<th>Age(year-old)</th>
<th>Mean±SD</th>
<th>Range (Yrs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>57.8±12</td>
<td>31-78</td>
<td></td>
</tr>
<tr>
<td>Duration of dialysis(month)</td>
<td>40.2±48</td>
<td>11-204</td>
</tr>
</tbody>
</table>

Table 2 Biochemical data in all patients

<table>
<thead>
<tr>
<th>Dialysis duration(month)</th>
<th>Mean</th>
<th>Std. Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>40.29</td>
<td>48.3</td>
<td></td>
</tr>
<tr>
<td>Calcium (mg/dl)</td>
<td>8.53</td>
<td>0.79</td>
</tr>
<tr>
<td>Phosphorus (mg/dl)</td>
<td>5.812</td>
<td>1.72</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/l)</td>
<td>462.18</td>
<td>202.76</td>
</tr>
<tr>
<td>Hemoglobin (mg/dl)</td>
<td>1.14</td>
<td>1.46</td>
</tr>
<tr>
<td>Creatinine (mg/ml)</td>
<td>8.65</td>
<td>2.13</td>
</tr>
<tr>
<td>Sodium (mEq/l)</td>
<td>139.18</td>
<td>3.34</td>
</tr>
<tr>
<td>Fasting Blood Sugar(mg/dl)</td>
<td>106</td>
<td>47.87</td>
</tr>
<tr>
<td>Platelet[*103µl]</td>
<td>173.18</td>
<td>68.13</td>
</tr>
</tbody>
</table>

Discussion

The existed data about the influence of hemodialysis among ESRD patients is limited; most of the studies have been dedicated to predialysis, HD and renal transplanted patients and occasional information is accessible for patients on peritoneal dialysis, hemofiltration and hemodialfiltration.6-11

In our study simple regression analysis showed no correlation between serum sodium and dialysis duration. Similarly, no correlation was found between age and serum biomarkers.

Serum Ca and P displayed a significant correlation only with duration of HD as expected which were in line with other previous reports.1,11-13 The differences between our results in comparison with other previous studies may be because of our limited sample size.

Conclusion

Remarkably, the duration of hemodialysis does act to disturb bone related serum biomarkers like ALP, Ca, and P; with some patients remaining outside the standard range for serum calcium and phosphorus range, practical guidelines and adequate treatment should be followed to reduce any other further risk of secondary hyperparathyroidism and its complications. Besides, the impact of other factors on bone metabolism and bone mineral density changes in HD patients importantly remains to be illuminated with further studies.

Acknowledgments

We’d like to appreciate the all Hemodialysis Ward Staff of Sayyad Shirazi Hospital and 5thAzar Hospitals (Gorgan, Iran) for their sincere contribution to the study.

Conflict of interest

The author declares there is no conflict of interest.

References